Richard R. Furman, MD
The combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) could possibly change the treatment landscape for patients with chronic lymphocytic leukemia (CLL).
In an interview prior to ASH conducted at the 35th annual CFS®, Richard Furman, MD, director of the CLL Research Center at Weill Cornell Medicine, discussed the current management of CLL and the future of combinations, including venetoclax and ibrutinib, for this patient population.
OncLive: Can you please provide an overview of your presentation on CLL at the 35th annual CFS?
: The main point of my talk was to identify where our patients’ current therapy is failing. I used ibrutinib as the paradigm for what I believe is the best upfront treatment for patients. I identified the patients who are not going to be able to enjoy the long-term progression-free survival of ibrutinib with the hope of being able to predict who those patients are ahead of time.
What combinations with ibrutinib have been successful?
Ibrutinib is being combined with everything. The study that is going to be the most important to changing the treatment paradigm is the ibrutinib plus venetoclax trial. The patients are receiving 3 months of ibrutinib as a single agent and then are going to receive venetoclax in combination for 12 months.
... to read the full story